Biktarvy®: Post-Exposure Prophylaxis

Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information. Some of the data may be outside of the US FDA-approved Prescribing Information. Gilead Sciences, Inc. does not intend to offer an opinion regarding the clinical relevance of these data or the advisability of administering any drug in a manner inconsistent with its approved labeling.

This document is in response to your request for information regarding Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]) and its use for HIV-1 infection post-exposure prophylaxis. Please be aware that BIC/FTC/TAF is not indicated for PEP in the US.¹

The full indication, important safety information, and boxed warnings are available at:
http://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi

Ongoing Clinical Trial
Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP) Study

Study Design and Available Baseline Demographics²,³

This is an ongoing, phase 4, non-randomized, single site, open label single arm trial to evaluate the safety, tolerability, and acceptability of a fixed-dose formulation of BIC/FTC/TAF for prophylaxis following potential non-occupational exposure to HIV-1. Key inclusion criteria are HIV uninfected and possible sexual exposure to HIV-1 recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure. Participants receive BIC/FTC/TAF for 28 days and are seen for 3 visits over a period of four months. The primary endpoints are nPEP failure as measured by HIV seroconversion during study participation, and safety and tolerability of BIC/FTC/TAF. Currently available baseline demographics for the first 48 participants enrolled in the study are listed in Table 1.³ Additional information regarding this study is available at www.clinicaltrials.gov (NCT03499483).

Table 1. Available Baseline Demographics (Mayer et al.)³

<table>
<thead>
<tr>
<th>Age, median years (range)</th>
<th>BIC/FTC/TAF (N=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race/ethnicity, %</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>79.2</td>
</tr>
<tr>
<td>Mixed</td>
<td>12.4</td>
</tr>
<tr>
<td>Hispanic/Latino ethnicity</td>
<td>8.3</td>
</tr>
<tr>
<td>Black/African American</td>
<td>4.2</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>4.2</td>
</tr>
<tr>
<td>Sexual Orientation/Gender Identity, %</td>
<td></td>
</tr>
<tr>
<td>Gay/CG Male</td>
<td>75.0</td>
</tr>
<tr>
<td>Bisexual/CG Male</td>
<td>12.5</td>
</tr>
<tr>
<td>Heterosexual/CG Male</td>
<td>4.2</td>
</tr>
<tr>
<td>Heterosexual/CG Female</td>
<td>4.2</td>
</tr>
<tr>
<td>Queer/Transgender Male</td>
<td>2.1</td>
</tr>
<tr>
<td>Don’t Know/CG Male</td>
<td>2.1</td>
</tr>
</tbody>
</table>

¹The full indication, important safety information, and boxed warnings are available at: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi

²Intended for U.S. Healthcare Professionals only

³Last Updated: 18 Mar 2020
Results To Date

At present, 48 participants have completed the study. No HIV seroconversions were detected among these participants. Reasons for initiating nPEP include receptive anal intercourse (49.7%), insertive anal intercourse (43.6%), receptive oral intercourse (15.4%), and insertive or receptive vaginal intercourse (7.7% for each). Two participants were lost to follow-up; 85.4% of the remaining participants completed the 28-day BIC/FTC/TAF course.

The most commonly reported adverse events included nausea with or without vomiting (15%), fatigue (6%), and diarrhea (6%). All adverse events were grade 1, except for a single report of grade 2 fatigue which was associated with discontinuation of BIC/FTC/TAF. Lab abnormalities were observed in 3 participants (increased transaminases [2], decreased CrCl [1]) and lab values returned to normal upon completion of the BIC/FTC/TAF course.

When compared to historical PEP regimens AZT/3TC/PI, FTC/TDF + RAL, and E/C/F/TDF, participants using BIC/FTC/TAF for PEP were statistically more likely to complete the regimen as prescribed and less likely to experience diarrhea, headache, and dizziness/lightheadedness.

References

1. Enclosed, Gilead Sciences Inc. BIKTARVY® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. US Prescribing Information. Foster City, CA. In.

Abbreviations

3TC=lamivudine
AZT=zidovudine
BIC=bictegravir
CG=cisgender
CrCl=creatinine clearance
E/C/F/TDF=elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
FTC=emtricitabine
PEP=post-exposure prophylaxis
PI=protease inhibitor
RAL=raltegravir
TAF=tenofovir alafenamide
TDF=tenofovir disoproxil fumarate

Intended for U.S. Healthcare Professionals only
Last Updated: 18 Mar 2020
Product label

For the full indication, important safety information, and Boxed Warning(s), please refer to the Biktarvy US Prescribing Information available at: http://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.

Follow up

For any additional questions, please contact Gilead Medical Information at:
☎ 1-866-MEDI-GSI (1-866-633-4474) or https://www.gilead.com/medicines/request-information

Adverse event reporting

Please report all adverse events to:
Gilead Pharmacovigilance and Epidemiology ☎ 1-800-445-3235, option 3
FDA MedWatch Program by ☎ 1-800-FDA-1088 or MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or www.accessdata.fda.gov/scripts/medwatch

Data privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead’s affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy/privacy-statement) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com

BIKTARVY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
© Gilead Sciences, Inc.